Introduction
Repeated administration of gene therapy for cystic fibrosis is likely to be essential for long-term clinical efficacy. Clinical trials of CFTR-gene therapy, which to date, number over 20, 1 have focused on recombinant adenoviruses, adeno-associated viruses or nonviral lipid vectors (cationic lipids) for gene transfer. While these vectors have been shown to be capable of gene transfer, none are integrating and even if efficiency of gene expression were optimized, it would likely be shortlived. The problems of repeat administration may be minimized by the use of slow-release preparations to deliver cDNA to the airway. These may result in more prolonged expression of the transgene and thus longer dosing intervals for the patient.
Systems capable of localized plasmid gene delivery for prolonged periods of time, without inflammatory or toxic consequences, have previously been reported. Bonadia et al 2 investigated the use of a collagenbased polymer matrix sponge in which plasmid DNA encoding human parathyroid hormone was physically entrapped (gene activated matrix, GAM). Implantation of these GAMs at sites of bone injury in vivo was shown to be associated with retention and expression of the cDNA for at least 6 weeks and with the growth of normal new bone in a stable, reproducible, doseand time-dependent manner. In a slightly different system suitable for the controlled release of plasmid DNA, Ochiya et al 3 described cylindrical 'minipellets' comprising atelocollagen embedded with plasmid DNA encoding the growth factors HST-1/FGF-4. Injection of the minipellets into skeletal muscle of mice in vivo was associated with gene expression prolonged for up to 40 days with a consequential functional increase in platelet counts demonstrable for up to 60 days.
Slow-release preparations of cDNA specifically designed for pulmonary gene delivery have, to date, not been reported. Neither GAMs nor the minipellet would be suitable for the airways. However, a number of particulate systems, potentially more suitable for topical delivery to the lungs, have been described. Controlled delivery of genes has, for example, been demonstrated using gelatin-DNA nanospheres. 4 These spherical particles (200-700 nm) contained 25-30% DNA and were capable of transfecting cultured cells in vitro. Further, intramuscular injection of the nanospheres into mice in vivo was associated with greater and more prolonged expression of the reporter gene encapsulated compared with an equivalent dose of naked DNA or lipofectamine-DNA. DNA has also been formulated with the synthetic, biodegradable polymer, poly(lactide-co-glycolide) (PLG) to generate microparticles capable of sustained gene delivery and expression. [5] [6] [7] PLG, which has a history of safe application in humans, 8 has been used extensively in the development of vaccine technology, [9] [10] [11] and may be loaded with biologically active molecules of widely different molecular size including insulin, 12 prolidase, 13 camptothesin 14 and rhVEGF. 15 pDNA encapsulated in PLG remains stable, and protected from enzymatic degradation. 5, 16 In this study, we have explored the potential use of PLG microspheres for sustained gene delivery and expression in airway epithelium, with a view to further application for cystic fibrosis gene therapy. Following formulation and characterization of the microspheres, gene transfer efficiency and duration of transgene expression have been tested in vitro on both non-CF and CF cell lines, ex vivo in a model using native sheep trachea and finally in vivo by instillation into the lungs of Balb/C mice. We demonstrate that the system results in low levels, but sustained expression of the transgene for up to 2 weeks in vivo.
Results

Characterization of PLG-microspheres
Scanning electron microscopy of microsphere preparations ( Figure 1 ) showed spherical particles, 3.0-5 mm in size. Laser spectrophotometry of suspensions of microspheres confirmed that B50% of particles were o5.2 mm. Larger particles were likely aggregates as microscopy showed that B80% particles were o5 mm. Extraction and quantification of pDNA from PLG-microsphere preparations, showed an encapsulation efficiency of 50.772.3% (n¼6). Further, analysis of the extracted pDNA using gel electrophoresis (n¼4), confirmed that the preparation process did not degrade the pDNA. As depicted in one example (Figure 2 ), pDNA extracted from the microspheres was present in the supercoiled, linear and relaxed conformations. Compared to untreated pDNA, there was however a marked decrease in the proportion of supercoiled DNA whereas the proportion of linear and relaxed DNA increased.
Release kinetics experiments were carried out in vitro in TE buffer (pH 7.4) at 371C and the results are depicted as percentage release from total remaining DNA at 24-h time intervals (Figure 3a ) and as cumulative release of total DNA from the original preparation (Figure 3b) . After an initial burst in which 24.974.3% (n¼4) of total entrapped DNA was released within 24 h (Figure 3a) , DNA release from remaining entrapped DNA decreased progressively to 7.272.3%/24 h by day 4 and then was sustained at 1.670.5%/24 h until day 14. There was no further detectable DNA release from the polymers after this time. Reanalysis of the same data as cumulative release of DNA from the PLG microspheres (Figure 3b ) reveals that some degree of DNA loss occurs over time, probably secondary to degradation. Thus, by day 15, when no further DNA release was detected, 70.073.3% of pDNA originally loaded into the microspheres could be accounted for.
Duration and efficiency of gene transfer in vitro
Transfection efficiency of the PLG polymers encapsulating the reporter gene b-galactosidase (b-gal) was tested (Figure 4a ) and in the CF airway epithelial cell line CFTEoB (Figure 4b ). In each case, transfection efficiency was compared with the cationic lipid #67. The pattern of PLG-mediated transfection was similar in both cell lines, demonstrating lower efficiency than lipid #67 at 24 h, but sustaining original levels to 48 h. Thus, after 24 h, lipid-#67-mediated transfection resulted in more than double the amount of detectable b-galactosidase compared to the PLG-mediated transfection. However, by 48 h, the b-gal expression in cells transfected with lipid #67 was only 50.3713.7 and 38.272.7% (for Cos 7 and CFTEoB cells, respectively) of that detected at 24 h. In comparison, expression levels from PLG-mediated transfections were sustained at 48 h, being 70.7717.9 and 120.1711.8% of the 24-h level in Cos and CFTEoB cells, respectively.
Duration and efficiency of gene transfer ex vivo
The transfection efficiency of PLG polymers was also tested on sheep trachea in an ex vivo model. 16 Transgene expression was assayed for up to 96 h and again compared with lipid-#67-mediated gene transfer. 
Duration and efficiency of gene transfer in vivo
In order to test their gene transfer potential in vivo, PLG polymers encapsulating pDNA encoding the reporter Figure 3 Release kinetics of PLG-encapsulated pDNA studied in vitro. Following incubation of the microspheres in TE buffer (pH 7.4, 371C), the buffer was separated from the spheres by centrifugation and the DNA content of the supernatant analysed by spectrophotometry (260 nm). The percentage released from the total remaining DNA entrapped within the microspheres at each 24-h time point was calculated (mean7s.e.m., n¼4) (a). In order to determine whether all the original loaded DNA could be accounted for, the cumulative release (% of original amount loaded) was recalculated (b). Controlled release gene therapy for airway epithelium M Stern et al gene chloramphenicol acetyl transferase (CAT) 17 were instilled intranasally into the lungs of Balb/C mice. As shown in Figure 6 , CAT expression was barely detectable in mouse lungs transfected with PLG-CAT when measured at 48 h. However, levels progressively rose and were significantly (Po0.001) higher than that detected in lipid-#67-treated lungs when remeasured at 7 days and then at 14 days, respectively. Detectable gene expression was sustained to day 21. This profile of gene expression contrasted with that observed following lipid-#67-mediated gene transfer where, compared to PLG-CAT, significantly (Po0.001) higher levels were detected at 48 h. These levels were however not sustained after 48 h. There was no detectable CAT expression in the lungs of control mice instilled with PLG microspheres encapsulating the 'irrelevant' plasmid encoding b-gal.
Discussion
In these studies, we have demonstrated the use of the biodegradable, biocompatible polymer, PLG, for encapsulation and subsequent delivery of plasmid DNA to airway epithelial cells in vitro, ex vivo and in vivo. Following preparation of the PLG-DNA microspheres using a double emulsion and solvent evaporation technique, the particles were characterized with respect to size, encapsulation efficiency, release kinetics and DNA conformation. Although transfection efficiency is lower than that achievable using the second-generation cationic lipid #67, duration of expression is more sustained.
PLG microspheres have a number of potential advantages for gene therapy. First, their use has general applicability to different plasmids and there is no size limitation on the size of the encapsulated gene. This is particularly useful for transferring CFTR cDNA, with its coding region of 230 kB. 18 Secondly, formulation of the microparticles is relatively simple and results in high efficiency of DNA encapsulation (B50%). Third, the preparation is stable 5 and suitable for resuspension at concentrations that allow for administration of small volumes in vivo. This is in contrast to preparation of gelatin-DNA nanoparticles, 4 which have lower encapsulation efficiency and where the final concentration of the suspension requires administration of large volumes to achieve optimal cDNA transfer (data not shown). Finally, PLG microspheres have the potential for encapsulation of other bioactive molecules, such as drugs, peptides or cytokines. For CF, this may offer the attractive possibility of combining gene transfer with antibacterial or antiinflammatory therapy in a single delivery system. Concomitant downregulation of infection and inflammation may in itself improve transfection efficiency by decreasing some of the extracellular barriers to airway gene transfer. 16 A number of potential disadvantages of PLG microspheres also emerged from this study. Gene transfer efficiency, particularly in vivo, is likely too low for clinical efficacy, even though the vexed question of the level of gene expression needed to achieve clinical benefit in CF remains unresolved. It is possible that low but sustained levels, rather than high but short-lived levels, of transduced CFTR may be required. It has been suggested, for example, that only 6-10% of cells within a monolayer of CF epithelial cells must be 'corrected' in order to restore normal chloride transport, 19 although the percentage required to correct the sodium transport defect has been shown to be much higher than this. 20 Thus, the optimal strategy for functional correction would probably be to mimic normal expression, that is, to correct as close to 100% of cells as possible at low levels of expression per cell. Sustained release of cDNA onto the target cell population using a system like PLG microspheres may be more suitable than high efficiency, short-lived vectors, with a realistic aim of achieving somewhere between 10 and 100% of cells. Further, since sustained release of cDNA is likely to result in lower doses, it is possible that this system may also result in lower toxicity for the lung. Clarification of the type of cells preferentially tranduced by PLG microspheres has, however, still to be achieved. Preferential transduction of the alveolar epithelium would clearly be of little therapeutic benefit in CF. Currently, lipid-mediated reporter gene transfection efficiency in the lungs remains too low for detection by standard histochemical technology. Given that PLG-mediated transfection efficiency, while more durable, is even lower than lipid #67, it was not possible to determine the specific cell type transfected using this system. Nevertheless, significant improvements upon the gene transfer efficiency demonstrated in these studies would most likely still be required even if sustained, low-level gene transfer proved to be optimal. This may involve optimization of one or more of the many different factors that can influence the gene transfer efficiency of PLG microparticles, including size, structure, density, degradation pattern, method of delivery to recipient cells and final conformation of the released DNA. Control of microsphere size distribution has, for example, been shown to have important implications for release of its contents. Spheres that are 'too small' (o5 mm) may release their contents too rapidly. Larger spheres generally release encapsulated compounds more slowly and over longer time periods, but may not easily pass through a syringe needle or be appropriate for nebuliza- Figure 6 In vivo expression of the reporter gene CAT administered intranasally into the lungs of Balb/C mice using either PLG microspheres or lipid #67. PLG microspheres encapsulating an irrelevant plasmid, b-gal, were instilled into a control group of mice. Whole lung CAT expression was measured at 48 hs, and then at 1, 2 and 3 weeks after transfection. Error bars indicate mean7s.e.m., n¼6 for each group of animals at each time point. **¼Po0.01 compared to lipid-#67-mediated gene expression at day 7 and day 14, respectively. *¼Po0.05 compared to lipid-#67-mediated gene expression at day 21.
Controlled release gene therapy for airway epithelium M Stern et al tion. A novel method for production of microspheres of precisely controlled and/or monodisperse size distribution has recently been described 21 but has not, to date, been tested for encapsulation of plasmid DNA. Polymer thickness and architecture, which in turn determines degradation and diffusion characteristics, are other factors which may determine the efficacy of DNA release and hence gene transfer efficiency. 22 Both hydration and pH affect these characteristics, and need to be taken into account when considering delivery of the particles to an inflamed lung where increased secretions and bacterial colonization may alter these factors. Delivery of the microspheres to the lower airways would most likely be achieved by nebulization. Nebulization of pharmacological agents encapsulated in PLG has been described, particularly for airway delivery of antituberculous therapy, 23 but the effect of nebulization on PLG-encapsulated plasmid DNA has not yet been studied. While encapsulation of the DNA potentially offers a way to both protect DNA from degradation 15 and also control its release, 7 analysis of DNA extracted from our microspheres, as well as in previous studies, 6 revealed a relative increase in the amount of nicked DNA compared to supercoiled. Whether this translates into loss of transfection efficiency remains unclear. There is evidence to suggest that relaxed forms of DNA are no less efficient at gene delivery than supercoiled forms. 24 Further, when Hao et al 25 analysed DNA released from PLG microspheres over 14 days, they demonstrated a gradual conversion of supercoiled plasmid to the nicked isoform but showed no consequent reduction in the biological activity of this DNA, as measured by transfection of COS-7 cells in vitro. The use of linear DNA however, resulted in markedly lower transfection efficiency, and steps to minimize sequential degradation of encapsulated DNA from nicked to linear forms may be important.
The mechanism by which these microspheres enter cells and deliver their contents to the nucleus is unclear. Degradation of the polymer could occur outside the cell, with slow release of the packaged DNA onto the cell surface where it is internalized, or the microspheres, may be taken up into cells followed by slow release of their contents. We speculate that the latter is more likely. Thus, in the upper airways, ciliated epithelial cells contribute to the mucociliary escalator by which particles are rapidly swept from the airways towards the mouth. In the more distal airways and alveoli, macrophages capable of phagocytosis clear particles soon after deposition. An extracellular site of action would therefore require a means of avoiding or suspending the lungs' natural clearance mechanisms until the encapsulated DNA is effectively delivered. This may depend partially on the size and porous nature of the particles. Particles of 1-5 mm in diameter would likely be engulfed by antigen-presenting cells such as macrophages. 26, 27 Edwards et al 28 have, however, demonstrated that larger, but very light particles permitted highly efficient delivery of inhaled particles into the systemic circulation. Thus particles with mass densities of o0.4 g/cm 3 and mean diameters exceeding 5 mm were inspired deep into the lungs and escaped the lungs' natural clearance mechanisms until the inhaled particles delivered their therapeutic contents. Optimization of microparticle preparation would clearly also need to take density parameters into account.
In conclusion, these studies demonstrate that PLG microspheres are capable of cDNA delivery to airway epithelium where the transgene is expressed at low, but sustained levels for up to 2 weeks in vivo. This raises the possibility of a system that could be used for slowrelease airway gene therapy for CF, although significant improvements in gene transfer efficiency will be required.
Methods
Materials
pDNA encoding the reporter genes CAT 17 under control of a cytomegalovirus (CMV) promoter and a hybrid intron and b-gal 29 under control of a CMV promoter were used for liposome-mediated gene transfer. PLG 50:50 mw 50 000-70 000, poly-(L-lysine) (PLL) mw 25 0000, and polyvinyl alcohol (PVA) mw 30 000-70 000 were supplied by Sigma-Aldrich Chemicals, Gillingham, Dorset, UK. All other chemicals were obtained commercially as analytical grade reagents.
Preparation of the PLG-encapsulated DNA polymers
Microspheres of PLG were prepared by a method adapted from the one previously described. 5 Briefly, pDNA was complexed with PLL by rapid mixing of pDNA in Tris-EDTA buffer with PLL (pDNA/PLL ratio 1:0.3). The microspheres were prepared by dispersing an aqueous solution of pDNA/PLL complex into a 6% (w/w) solution of PLG in methylene chloride made up in a glass container and vortexed for 2 min. This dispersion was then injected using a glass pipette into an aqueous 4% PVA solution containing 10% sucrose (50 ml) while being mixed (Silverson laboratory mixer-L4R, Silverson Machines Inc., UK) The solvent was extracted by transferring the resulting emulsion into a 0.35% PVA solution containing 10% sucrose (50 ml) and stirring for 1 h at 371C. Finally, the microspheres were recovered by filtration through a 0.22 mm filter. They were washed while on the filter paper by passing large volumes of deionized water through the filter, dried on the filter paper overnight at room temperature and then removed and stored at room temperature in a dry environment.
Microsphere characterization
Field-emission scanning electron microscopy (400S, Hitachi, Mountain Veiw, CA, USA) and laser light scattering (Malvern Instruments SB.09, UK) were used to determine morphology and size of the PLG-pDNA microspheres. For laser light scattering, the particles were suspended in sterile distilled water. To determine the amount and structural integrity of pDNA incorporated during preparation of the PLG microspheres, pDNA was extracted from the microspheres using a method previously described. 6 Briefly, the microspheres (10 mg) were dissolved in chloroform (1.5 ml) and the pDNA extracted by serial ( Â 5) additions of TE buffer (0.5 ml each time). pDNA content was analysed by spectrophotometry (Unicam UV1, ThermoSpectronic, Cambridge, UK) at 260 nm. The limit of detection of DNA extracted from PLG microspheres by UV spectrophotometry has previously been shown to be B0.05 mg Controlled release gene therapy for airway epithelium M Stern et al DNA/mg PLG. 30 Purity and structural integrity of the pDNA was analysed by gel electrophoresis (1% agarose containing 0.1 mg% ethidium bromide in 1XTAE buffer, 100 V, 2 h). In vitro release kinetics were determined by suspension of PLG microspheres (20 mg) in TE buffer (pH 7.4), incubation on a shaking table (100 rpm) at 371C, and separation of the buffer from the microspheres at 24-h intervals by centrifugation. The DNA content of the supernatant was analysed by spectrophotometry at each of these time points and the remaining microspheres resuspended in fresh buffer.
Cell culture
All media were obtained from Gibco BRL, Paisley, UK. The SV-transformed epithelial cell line Cos 7 31 was maintained at 371C/5% CO 2 in Dulbecco's modified Eagles medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 1% L-glutamine and 1% penicillin/ streptomycin. The CF submucosal epithelial cell line 32 were maintained in minimal essential medium (MEM) supplemented with 10% FBS, 1% penicillin/streptomycin, 1% L-glutamine and nonessential amino acids.
In vitro transfection
Cells were plated in six-well, tissue-culture grade plates (Greiner Labortechnik) and maintained at 371C/5% CO 2 until 60-70% confluent in their respective growth media. Cells were then washed with PBS (pH 7.4) and the medium replaced with 1 ml OptiMEM (Gibco BRL). PLG microspheres encapsulating b-gal cDNA were suspended in medium and added to each well (B5 mg DNA/well). Alternatively, an equivalent amount of DNA complexed with the cationic liposome, GL #67 (Genzyme, Framingham, MA, USA) was added to control wells. All complexing reactions were carried out at a molar ratio of 1:4 (lipid:DNA) where the molarity of lipid #67 was 1.2 mM and the molarity of the DNA was calculated, based upon the assumption that the molecular weight of nucleotides in 330 g/mol. 33 The media were removed after 24 or 48 h. The cells were washed twice with PBS, and lysed in a solution containing 0.1% Triton X-100 and 250 mM Tris (pH 8, 500-ml per well) prior to undergoing three freeze/thaw cycles (À801C Â 30 min/371C Â 5 min). The cell lysate was assayed for b-gal using a luminescent reporter system (Clontech Laboratories Inc., Palo Alto, USA) according to the manufacturer's suggested protocol. To minimize the effects of differing cell numbers and cell growth, the amount of b-gal expression obtained was standardized by calculation of the amount of protein present in each cell lysate. Protein was assayed using the Bradford method 34 in a microassay protocol adapted for use in 96-well plates (Bio-Rad, Hemel Hempstead, UK), read at 595 nm. Absorption readings were converted to microgram protein using a bovine serum albumin standard curve. Thus data are expressed as pg b-gal/mg protein.
Preparation of sheep trachea
Sheep trachea 16 2 ) and transported to the laboratory on ice. To remove the mucus, the noncartilaginous sections were cut longitudinally to leave horse-shoe-shaped segments that were placed in 10 mm Petri dishes containing MEM with 50 mg/ml gentamycin and 1 Â antibiotic/antimycotic solution (MEM-A) with the tips of the cartilage submerged in the media. These were then placed on a shaking platform in a waterbath at 371C such that the base of the dish was submerged in the bath and left for 18 h. Subsequently, the epithelial layer was dissected free of the majority of muscle and adventitia, cut into 0.5 cm 2 (approximately) pieces and the viability checked by observing ciliary beating. Each piece of tissue was placed at an air-liquid interface as follows: a 35 mm Petri dish was aseptically placed within a 55 cm Petri dish, and a filter paper (Whatman No. 1, A1 Laboratory Supplies, London, UK) laid out across the inner dish such that its ends reached to the outer container. MEM-A (4 ml) was placed in the outer dish allowing the filter paper to act as a wick. Each piece of epithelial tissue was placed on the wick in the centre of the inner dish. A rubber 'O' ring (Altec, Alton, UK) of internal diameter 3 mm was placed on the tissue square and sealed in place with 5-10 ml 1% agarose to allow for prolonged surface contact.
Ex vivo transfection
Each tissue piece was transfected with 2 mg b-gal cDNA either encapsulated within PLG microspheres (suspended in medium such that 5-ml suspension contained 2 mg encapsulated DNA), or complexed with lipid #67 as described above. The 5 ml aliquot was carefully added to the apical side of the tissue avoiding any contact with the tissue surface. Tissues were then incubated at 371C/5% CO 2 for 48, 72 or 96 hs, respectively without any intervention. After the required incubation, tissue samples were placed in 0.5 ml Tris buffer (0.25 M, pH 8) and homogenized for 15 s at 24 000 rpm (Ultra-Turrax T25, Janke and Kunkel, IKA Labortechnik, Staufen, Germany). Expression of CAT was determined as previously described. 35 
In vivo transfection
Adult male Balb/C mice of weights between 17 and 23 g (Charles River, Kent, UK) were used. The animals were maintained in a pathogen-free environment at 191C 50% humidity and had unlimited access to food and water. Animals were individually anaesthetized in a closed chamber using the inhalational anaesthetic methoxyflurane (Metofane, Mallingkrocdt Veterinary, Mundlein, IL, USA). Each animal was removed from the chamber and held vertically while pressure was applied to the lower mandible to immobilize the tongue and prevent swallowing. PLG polymers (encoding either b-gal or CAT, 80 mg DNA in a total volume of 40 ml) or lipid #67-DNA complexes (80 mg pCF1-CAT in a total volume of 100 ml) were applied dropwise on to the nostrils of the animal and the mixture was inhaled by sniffing. All complexing reactions with lipid #67 were carried out so that equal volumes of lipid (1.2 mM) were added to the pDNA (4.8 mM; the calculation of molarity of the pDNA based upon the assumption that the molecular weight of the nucleotides is 330 g/mol).
Statistical analysis
All data are presented as mean7s.e.m. for convenience where n refers to the number of individual experiments or animals. The Mann-Whitney U-test was used for 
